PMID- 36294953 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221030 IS - 2075-1729 (Print) IS - 2075-1729 (Electronic) IS - 2075-1729 (Linking) VI - 12 IP - 10 DP - 2022 Sep 29 TI - Switching from Adalimumab Originator to Biosimilar in Patients with Hidradenitis Suppurativa Results in Losses of Response-Data from the German HS Registry HSBest. LID - 10.3390/life12101518 [doi] LID - 1518 AB - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically. FAU - Kirsten, Natalia AU - Kirsten N AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. FAU - Ohm, Frenz AU - Ohm F AUID- ORCID: 0000-0002-0177-1283 AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. FAU - Gehrdau, Kathrin AU - Gehrdau K AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. FAU - Girbig, Gefion AU - Girbig G AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. FAU - Stephan, Brigitte AU - Stephan B AUID- ORCID: 0000-0001-6127-3692 AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. FAU - Ben-Anaya, Nesrine AU - Ben-Anaya N AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. FAU - Pinter, Andreas AU - Pinter A AUID- ORCID: 0000-0002-1330-1502 AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. AD - Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt, 60590 Frankfurt am Main, Germany. FAU - Bechara, Falk G AU - Bechara FG AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. AD - Department of Dermatology, Venereology and Allergology, Ruhr-University Bochum, 44791 Bochum, Germany. FAU - Presser, Dagmar AU - Presser D AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. AD - Department of Dermatology, Venerology and Allergology, University Hospital Wurzburg (UKW), 97080 Wurzburg, Germany. FAU - Zouboulis, Christos C AU - Zouboulis CC AUID- ORCID: 0000-0003-1646-2608 AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. AD - Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, 06847 Dessau, Germany. FAU - Augustin, Matthias AU - Augustin M AD - Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), 20251 Hamburg, Germany. AD - European Hidradenitis Suppurativa Foundation e.V., 06847 Dessau, Germany. LA - eng PT - Journal Article DEP - 20220929 PL - Switzerland TA - Life (Basel) JT - Life (Basel, Switzerland) JID - 101580444 PMC - PMC9605653 OTO - NOTNLM OT - TNF alpha OT - adalimumab OT - adverse drug reaction OT - biologics OT - biosimilar OT - drug effectiveness OT - hidradenitis suppurativa OT - registry OT - switching COIS- N.K. reports personal speaking fees, consulting fees and support for attending meetings from Janssen, AbbVie, Almirall, Lilly, Pfizer, UCB, Celgene and Uluru. F.G.B. reports personal speaking fees, consulting and grants for clinical studies from AbbVie, Novartis, Incyte, UCB, Janssen and Boehringer Ingelheim. C.C.Z. reports personal speaking fees, consulting, grants, advisory board participation and medial writing for studies from AbbVie, Novartis, Boehringer Ingelheim, UCB, Regeneron, Bayer Healthcare, Inflarx and Janssen. M.A. has received consulting and speaking fees from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Janssen, LEO, Medac, Merck, MSD, Novartis, Pfizer, UCB and XenoPort and has been involved in clinical trials for AbbVie, Novartis and UCB to AI/HS as an investigator. F.O., K.G., G.G., B.S., N.B.-A., A.P. and D.P. claim no conflict of interest. EDAT- 2022/10/28 06:00 MHDA- 2022/10/28 06:01 PMCR- 2022/09/29 CRDT- 2022/10/27 01:34 PHST- 2022/08/29 00:00 [received] PHST- 2022/09/26 00:00 [revised] PHST- 2022/09/27 00:00 [accepted] PHST- 2022/10/27 01:34 [entrez] PHST- 2022/10/28 06:00 [pubmed] PHST- 2022/10/28 06:01 [medline] PHST- 2022/09/29 00:00 [pmc-release] AID - life12101518 [pii] AID - life-12-01518 [pii] AID - 10.3390/life12101518 [doi] PST - epublish SO - Life (Basel). 2022 Sep 29;12(10):1518. doi: 10.3390/life12101518.